SBWire

GlobalData's clinical trial report, "Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014" provides data on the Opioid Induced Bowel Dysfunction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opioid Induced Bowel Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opioid Induced Bowel Dysfunction. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData has released its pharma report, "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prophylactic hepatitis B virus vaccines Market. The report identifies and analyses the key companies shaping and driving the global prophylactic hepatitis B virus vaccines market. The report provides insight into the competitive prophylactic hepatitis B virus vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Glioblastoma Multiforme (GBM) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Glioblastoma Multiforme (GBM). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Glioblastoma Multiforme (GBM). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014" provides data on the Oral Cavity (Mouth) Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Cavity (Mouth) Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Oral Cavity (Mouth) Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Acute Myeloid Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Acute Myeloid Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Acute Myeloid Leukemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData has released its pharma report, "PharmaPoint: Migraine - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Heat Biologics, Inc. - Product Pipeline Review - 2014

GlobalData's clinical trial report, "Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014" provides data on the Natural Killer Cell Lymphomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Natural Killer Cell Lymphomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Natural Killer Cell Lymphomas. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Metastatic Uveal Melanoma Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Uveal Melanoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Uveal Melanoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Uveal Melanoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Advaxis, Inc. - Product Pipeline Review - 2014

GlobalData has released its pharma report, "PharmaPoint: Crohn's Disease - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Crohn's Disease Market. The report identifies and analyses the key companies shaping and driving the global Crohn's Disease market. The report provides insight into the competitive Crohn's Disease landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth

GlobalData's clinical trial report, "Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Colorectal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Colorectal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Colorectal Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

CEL-SCI Corporation today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection) has activated another U.S. clinical site at Southern Illinois University School of Medicine's Simmons Cancer Institute in Springfield, Illinois. The Illinois site, which has become part of the world's largest Phase III trial for head and neck cancer with dozens of hospitals and clinical centers in 12 countries, has now officially joined the study. According to the National Cancer Institute, researchers estimated that about 52,000 men and women in the U.S. will be diagnosed with head and neck cancers annually.

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

GlobalData's clinical trial report, "Pheochromocytoma Global Clinical Trials Review, H1, 2014" provides data on the Pheochromocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pheochromocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pheochromocytoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Papillary Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Papillary Renal Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Papillary Renal Cell Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Mucositis - Pipeline Review, H1 2014

Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2014

GlobalData's clinical trial report, "Malignant Fibrous Histiocytoma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Fibrous Histiocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Fibrous Histiocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Fibrous Histiocytoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Medulloblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Medulloblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Medulloblastoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.